COVID-19 Convalescent Plasma Therapy: Long-term Implications

Area of Science:

• Infectious Diseases
• Immunology
• Public Health

Background:

• The long-term effects of COVID-19 treatments on Post-Acute Sequelae of SARS-CoV-2 infection (PASC) remain largely unknown.
• Investigating the impact of COVID-19 convalescent plasma (CCP) on PASC symptoms and general health is crucial for understanding long-term recovery.

Purpose of the Study:

• To evaluate the 18-month efficacy of COVID-19 convalescent plasma (CCP) therapy in mitigating Post-Acute Sequelae of SARS-CoV-2 infection (PASC) symptoms.
• To assess the long-term impact of CCP on general health and Patient-Reported Outcomes Measurement Information System (PROMIS) scores in hospitalized COVID-19 patients.

Main Methods:

• The CONTAIN-Extend study followed 281 participants from the CONTAIN COVID-19 trial for 18 months post-hospitalization.
• Data collection included symptom surveys, global health assessments, and biospecimen analysis.
• Multivariable regression analyses were used to assess associations between CCP treatment arms and PASC symptoms, adjusting for relevant covariates.

Main Results:

• No significant differences in PASC symptoms or PROMIS scores were observed between the CCP and placebo groups.
• Female sex, age between 45-64 years, and enrollment during April-June 2020 were associated with increased general symptoms and poorer physical health.
• Hispanic and Black participants reported poorer physical health outcomes compared to White participants.

Conclusions:

• COVID-19 convalescent plasma (CCP) therapy showed no lasting benefit for Post-Acute Sequelae of SARS-CoV-2 infection (PASC) symptoms or overall health at 18 months.
• Demographic factors including sex, age, and the timing of acute infection are significant predictors of long-term symptom reporting and health outcomes after COVID-19 hospitalization.